Drugs / PCNAT-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07612930 | — | pancreatic ductal adenocarcinoma | Anda Biopharmaceutical Development (Shenzhen) Co., Ltd. | Available | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PCNAT-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07612930 ↗ |
| Modality | Vaccine | “PCNAT-01 is an investigational, personalized tumor neoantigen peptide vaccine composed of patient-specific synthetic peptides and Poly-ICLC.” NCT07612930 ↗ |
| Route | Subcutaneous | “PCNAT-01 is administered by subcutaneous injection” NCT07612930 ↗ |